Clinica e Investigacion en Arteriosclerosis最新文献

{"title":"Estándares de la Sociedad Española de Arteriosclerosis 2024 para el control global del riesgo vascular","authors":"José María Mostaza ,&nbsp;Xavier Pintó ,&nbsp;Pedro Armario ,&nbsp;Luis Masana ,&nbsp;José T. Real ,&nbsp;Pedro Valdivielso ,&nbsp;Teresa Arrobas-Velilla ,&nbsp;Ramón Baeza-Trinidad ,&nbsp;Pilar Calmarza ,&nbsp;Jesús Cebollada ,&nbsp;Miguel Civera-Andrés ,&nbsp;José I. Cuende Melero ,&nbsp;José L. Díaz-Díaz ,&nbsp;Javier Espíldora-Hernández ,&nbsp;Jacinto Fernández Pardo ,&nbsp;Carlos Guijarro ,&nbsp;Carles Jericó ,&nbsp;Martín Laclaustra ,&nbsp;Carlos Lahoz ,&nbsp;José López-Miranda ,&nbsp;José Puzo","doi":"10.1016/j.arteri.2024.02.001","DOIUrl":"10.1016/j.arteri.2024.02.001","url":null,"abstract":"<div><p>One of the objectives of the Spanish Society of Arteriosclerosis is to contribute to the knowledge, prevention and treatment of vascular diseases, which are the leading cause of death in Spain and entail a high degree of disability and health expenditure. Atherosclerosis is a multifactorial disease and its prevention requires a global approach that takes into account the associated risk factors. This document summarises the current evidence and includes recommendations for patients with established vascular disease or at high vascular risk: it reviews the symptoms and signs to evaluate, the laboratory and imaging procedures to request routinely or in special situations, and includes the estimation of vascular risk, diagnostic criteria for entities that are vascular risk factors, and general and specific recommendations for their treatment. Finally, it presents aspects that are not usually referenced in the literature, such as the organisation of a vascular risk consultation.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"36 3","pages":"Pages 133-194"},"PeriodicalIF":1.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0214916824000172/pdfft?md5=39f5d9b393096f14fbc00c313221dbe1&pid=1-s2.0-S0214916824000172-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140137301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Estándares de la Sociedad Española de Arteriosclerosis 2024 para el control global del riesgo vascular: Un documento de consulta imprescindible”","authors":"Fernando Civeira ,&nbsp;Rosa M. Sánchez-Hernández","doi":"10.1016/j.arteri.2024.04.003","DOIUrl":"https://doi.org/10.1016/j.arteri.2024.04.003","url":null,"abstract":"","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"36 3","pages":"Pages 126-127"},"PeriodicalIF":1.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140825833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impacto del tratamiento con rolipram sobre la homeostasis rédox y la señalización celular en un modelo experimental de aneurisma de aorta abdominal","authors":"Lídia Puertas-Umbert ,&nbsp;Judith Alonso ,&nbsp;Elena Roselló-Díez ,&nbsp;Alicia Santamaría-Orleans ,&nbsp;José Martínez-González ,&nbsp;Cristina Rodríguez","doi":"10.1016/j.arteri.2023.11.004","DOIUrl":"10.1016/j.arteri.2023.11.004","url":null,"abstract":"<div><h3>Introduction</h3><p>Cyclic nucleotide phosphodiesterases (PDEs) of the PDE4 subfamily are responsible for the hydrolysis and subcellular compartmentalization of cAMP, a second messenger that modulates vascular functionality. We had shown that PDE4B is induced in abdominal aortic aneurysms (AAA) and that PDE4 inhibition by rolipram limits experimental aneurysms. In this study we have delved into the mechanisms underlying the beneficial effect of rolipram on AAA.</p></div><div><h3>Methods</h3><p>AAA were induced in ApoE^-/− mice by angiotensin II (Ang II) infusion. Aneurysm formation was evaluated by ultrasonography. The expression of enzymes involved in rédox homeostasis was analyzed by real-time RT-PCR and the activation of signaling pathways by Western blot.</p></div><div><h3>Results</h3><p>Induction of PDE4B in human AAA has been confirmed in a second cohort of patients. In Ang II-infused ApoE^-/− mice, rolipram increased the percentage of animals free of aneurysms without affecting the percentage of aortic ruptures. Quantitative analyses determined that this drug significantly attenuated aortic collagen deposition. Additionally, rolipram reduced the increased <em>Nox2</em> expression triggered by Ang II, exacerbated Sod1 induction, and normalized Sod3 expression. Likewise, PDE4 inhibition decreased the activation of both ERK1/2 and the canonical Wnt pathway, while AKT activity was not altered.</p></div><div><h3>Conclusions</h3><p>The inhibition of PDE4 activity modulates the expression of enzymes involved in rédox homeostasis and affects cell signaling pathways involved in the development of AAA.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"36 3","pages":"Pages 108-117"},"PeriodicalIF":1.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138811748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detección de aterosclerosis subclínica mediante ecografía vascular como método de evaluación de riesgo vascular. Protocolo simplificado","authors":"Manuel Frías Vargas ,&nbsp;Estíbaliz Jarauta","doi":"10.1016/j.arteri.2024.03.003","DOIUrl":"https://doi.org/10.1016/j.arteri.2024.03.003","url":null,"abstract":"<div><p>Cardiovascular disease secondary to atherosclerosis is the main cause of morbidity and mortality in the world. Cardiovascular risk stratification has proven to be an insufficient approach to detect those subjects who are going to suffer a cardiovascular event, which is why for years other markers have been sought to help stratify each individual with greater precision. Two-dimensional vascular ultrasound is a excellent method for vascular risk assessment.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"36 3","pages":"Pages 195-199"},"PeriodicalIF":1.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S021491682400024X/pdfft?md5=917950dabec97cbd32281a780d5c2767&pid=1-s2.0-S021491682400024X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140824104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the IberScore model in a primary care population","authors":"Carlos Fernández-Labandera Ramos ,&nbsp;Irene Moral ,&nbsp;Carlos Brotons ,&nbsp;Luis Quevedo Aguado ,&nbsp;Inmaculada Coca Prieto ,&nbsp;Pedro Valdivielso ,&nbsp;Miguel Ángel Sánchez Chaparro","doi":"10.1016/j.arteri.2023.12.003","DOIUrl":"10.1016/j.arteri.2023.12.003","url":null,"abstract":"<div><h3>Background</h3><p>This study aimed to validate the IberScore cardiovascular risk model in a population attended in the primary care setting.</p></div><div><h3>Methods</h3><p>A cohort of patients with no history of cardiovascular disease visited in a primary care center during the years 2008 and/or 2009 and followed up until 2018 was selected.</p><p>Cardiovascular risk was calculated with the IberScore formula for all the subjects of the cohort and the model was calibrated, graphically represented by risk deciles the proportion of expected events and proportion of observed events at 10-year follow-up, stratified by sex. The area under the ROC curve was calculated to assess the discrimination of the model.</p></div><div><h3>Results</h3><p>A total of 10,085 patients visited during the years 2008 and/or 2009 were included in the study. Men showed a mean 10-year risk of suffering a fatal or non-fatal cardiovascular events according to IberScore of 17.07% (SD 20.13), with a mean estimated vascular age of more than 4 years higher than the biological age; while women had a mean 10-year risk of 7.91% (SD 9.03), with an estimated vascular age of more than 2 years above the biological age.</p><p>The area under the ROC curve showed a discrimination index of the model of 0.86 (95% CI 0.84–0.88) in men and 0.82 (95% CI 0.79–0.85) in women.</p></div><div><h3>Conclusion</h3><p>IberScore model discriminates well in the population attended in primary care but the model overestimates the risk.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"36 3","pages":"Pages 101-107"},"PeriodicalIF":1.6,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139467316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevención cardiovascular en la diabetes mellitus. ¿Es adecuado hablar de riesgo moderado o intermedio?","authors":"Sergio Martínez-Hervás ,&nbsp;José T. Real ,&nbsp;Rafael Carmena ,&nbsp;Juan F. Ascaso","doi":"10.1016/j.arteri.2023.10.003","DOIUrl":"10.1016/j.arteri.2023.10.003","url":null,"abstract":"<div><p>Diabetes, especially type 2, is considered a risk situation for atherosclerotic cardiovascular disease (ASCVD). Subjects with diabetes type 2 have a mortality rate due to ASCVD 3 times higher than that found in the general population, attributed to hyperglycemia and the frequent association of other cardiovascular risk factors, such as atherogenic dyslipidemia.</p><p>Numerous scientific societies have established a risk classification for ASCVD in diabetes based on 3 degrees (moderate, high and very high). The objectives of dyslipidemia control are clearly defined and accepted, and vary depending on the previously established cardiovascular risk.</p><p>In moderate or intermediate risk, the guidelines propose a less intensive intervention, maintaining LDL-C levels<!--> <!-->&lt;<!--> <!-->100<!--> <!-->mg/dL and NO-HDL-C levels<!--> <!-->&lt;<!--> <!-->130<!--> <!-->mg/dL, and waiting 10 years until reaching the high-risk category to initiate more intensive treatment. However, during the decade of follow-up recommended in the guidelines, cholesterol deposition in the arterial wall increases, facilitating the development of an unstable and inflammatory atheromatous plaque, and the development of ASCVD. Alternatively, diabetes could be considered from the outset to be a high-risk situation and the goal should be LDL-C<!--> <!-->&lt;<!--> <!-->70<!--> <!-->mg/dL. Furthermore, maintaining LDL-C levels<!--> <!-->&lt;<!--> <!-->70<!--> <!-->mg/dL contributes to reducing and stabilizing atheromatous plaque, avoiding or reducing mortality episodes due to ASCVD during those years of diabetes evolution.</p><p>Should we maintain the proposed objectives in subjects with diabetes and moderate risk for a decade until reaching the high cardiovascular risk phase or, on the contrary, should we adopt a more intensive stance from the beginning seeking to reduce cardiovascular risk in the majority of patients with diabetes? Is it better to wait or prevent with effective therapeutic measures from the first moment?</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"36 2","pages":"Pages 80-85"},"PeriodicalIF":1.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0214916823000979/pdfft?md5=6e42c0294316edb14f35e06619bd47a5&pid=1-s2.0-S0214916823000979-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138048164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias’ treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network metaanalysis","authors":"Konstantinos Pamporis ,&nbsp;Paschalis Karakasis ,&nbsp;Spyridon Simantiris ,&nbsp;Marios Sagris ,&nbsp;Konstantinos I. Bougioukas ,&nbsp;Nikolaos Fragakis ,&nbsp;Dimitrios Tousoulis","doi":"10.1016/j.arteri.2023.11.003","DOIUrl":"10.1016/j.arteri.2023.11.003","url":null,"abstract":"<div><h3>Objective</h3><p>Multiple systematic reviews (SR) have been performed on the effects of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), often providing conflicting findings. This overview and network meta-analysis (NMA) aimed to summarize SR<span> findings on the efficacy and safety of PCSK9i and provide an updated NMA.</span></p></div><div><h3>Materials and methods</h3><p>MEDLINE (Pubmed), Scopus, Cochrane, Epistemonikos and Google Scholar were searched from inception to September 21, 2023 for SRs of randomized controlled trials (RCTs) and from January 1, 2020 to September 21, 2023 for additional RCTs. Double-independent study selection, data extraction and quality assessment were performed. Qualitative analysis was performed for SRs and a frequentist random-effects model NMA was performed for RCTs.</p></div><div><h3>Results</h3><p><span><span>Totally, 86 SRs and 76 RCTs were included. Alirocumab (77/86 [90%]) and </span>evolocumab<span> (73/86 [85%]) were mostly analyzed. Associations from SRs (35/42 [83%]) and the updated NMA indicated PCSK9i benefit on major adverse cardiovascular events (MACEs). Reductions were also noted for cerebrovascular events (47/66 [71%]), coronary revascularization (29/33 [88%]) and myocardial infarction (41/63 [65%]). Alirocumab was associated with reductions on all-cause mortality (RR</span></span> <!-->=<!--> <span>0.82, 95%CI [0.72,0.94]). Data on any CV event reduction were conflicting (7/16 [44%]). Inclisiran appeared effective only on MACEs (RR</span> <!-->=<!--> <span>0.76, 95%CI [0.61,0.94]). No reductions in heart failure were observed (0/16). No increases were identified between PCSK9i<span> and any (0/35) or serious adverse events (0/52). However, PCSK9i were associated with injection-site reactions (20/28 [71%]).</span></span></p></div><div><h3>Conclusion</h3><p>PCSK9i appeared to be effective in CV outcomes and their clinical application was generally safe.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"36 2","pages":"Pages 86-100"},"PeriodicalIF":1.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138470964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the relationship between atherosclerosis and Helicobacter pylori infection with measurement of growth differentiation factor 15 and atherosclerosis indicators in adults with no comorbidity","authors":"Osman Başpinar ,&nbsp;Ayça Elibol ,&nbsp;Derya Koçer ,&nbsp;Turgut Tursem Tokmak ,&nbsp;Serkan Doğan ,&nbsp;Oğuzhan Sıtkı Dizdar","doi":"10.1016/j.arteri.2023.09.002","DOIUrl":"10.1016/j.arteri.2023.09.002","url":null,"abstract":"<div><h3>Background</h3><p>The aim of this study was to investigate presence of subclinical atherosclerosis by measuring carotid intima-media thickness (CIMT) in patients with <span><span>Helicobacter pylori</span></span><span> (HP) and to assess effects of HP on atherosclerosis by evaluating markers of atherosclerosis and blood growth differentiation factor (GDF-15) levels.</span></p></div><div><h3>Materials and methods</h3><p>This cross-sectional study included 59 patients without comorbid disease who had HP and 30 healthy controls without HP in upper endoscopic biopsy. In order to assess atherosclerosis, the CIMT measurement was performed by sonography. Serum GDF-15 level was measured by ELISA method. In all patients, atherosclerosis markers were recorded. Atherogenic indices were calculated, including Castelli risk index I and II (TG/HDL-c and LDL-c/HDL-c, respectively), plasma atherogenic index (PAI; log TG/HDL-c), non-HDL-c (TH-HDL-c) and atherogenic coefficient (AC; non-HDL-HDL-c).</p></div><div><h3>Results</h3><p>The GDF-15 level and CIMT were significantly higher in HP-positive group when compared to HP-negative group (<em>p</em> <!-->≤<!--> <!-->0.001). There was a significant correlation between serum GDF-15 level and CIMT (<em>r</em> <!-->=<!--> <!-->0.445; <em>p</em> <!-->≤<!--> <!-->0.001). There was no correlation between other atherosclerosis markers and serum GDF-15 level or CIMT. The bacterial intensity on endoscopic specimen was only correlated with CIMT (<em>p</em> <!-->&lt;<!--> <!-->0.001). Vitamin B12 and D levels were comparable among groups.</p></div><div><h3>Conclusion</h3><p>This study suggested that there was a correlation between GDF-15 level and subclinical atherosclerosis development in patients with HP. However, GDF-15 level, which was found to be elevated while atherogenic indices were normal, can be an earlier marker for subclinical atherosclerosis.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"36 2","pages":"Pages 51-59"},"PeriodicalIF":1.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49683446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influencia de la concentración de triglicéridos en la lipoproteína(a) en función de la dislipidemia","authors":"Victoria Marco-Benedí ,&nbsp;Ana Cenarro ,&nbsp;Martín Laclaustra ,&nbsp;Pilar Calmarza ,&nbsp;Ana M. Bea ,&nbsp;Àlex Vila ,&nbsp;Carlos Morillas-Ariño ,&nbsp;José Puzo ,&nbsp;Juan Diego Mediavilla Garcia ,&nbsp;Amalia Inmaculada Fernández Alamán ,&nbsp;Manuel Suárez Tembra ,&nbsp;Fernando Civeira","doi":"10.1016/j.arteri.2023.11.005","DOIUrl":"10.1016/j.arteri.2023.11.005","url":null,"abstract":"<div><h3>Background</h3><p>Recently, an inverse relationship between the blood concentration of lipoprotein(a) (Lp(a)) and triglycerides (TG) has been demonstrated. The larger the VLDL particle size, the greater the presence of VLDL rich in apoliprotein E and in subjects with the apoE2/E2 genotype, the lower Lp(a) concentration. The mechanism of this inverse association is unknown. The objective of this analysis was to evaluate the Lp(a)–TG association in patients treated at the lipid units included in the registry of the Spanish Society of Atherosclerosis (SEA) by comparing the different dyslipidemias.</p></div><div><h3>Patients and methods</h3><p>Five thousand two hundred and seventy-five subjects ≥18 years of age registered in the registry before March 31, 2023, with Lp(a) concentration data and complete lipid profile information without treatment were included.</p></div><div><h3>Results</h3><p>The mean age was 53.0 ± 14.0 years, with 48% women. The 9.5% of subjects (<em>n</em> = 502) had diabetes and the 22.4% (<em>n</em> = 1184) were obese. The median TG level was 130 mg/dL (IQR 88.0–210) and Lp(a) 55.0 nmol/L (IQR 17.9–156). Lp(a) concentration showed a negative association with TG concentration when TG values exceeded 300 mg/dL. Subjects with TG &gt; 1000 mg/dL showed the lowest level of Lp(a), 17.9 nmol/L, and subjects with TG &lt; 300 mg/dL had a mean Lp(a) concentration of 60.1 nmol/L. In subjects without diabetes or obesity, the inverse association of Lp(a)–TG was especially important (<em>p</em> &lt; 0.001). The median Lp(a) was 58.3 nmol/L in those with TG &lt; 300 mg/dL and 22.0 nmol/L if TG &gt; 1000 mg/dL. No association was found between TG and Lp(a) in subjects with diabetes and obesity, nor in subjects with familial hypercholesterolemia. In subjects with multifactorial combined hyperlipemia with TG &lt; 300 mg/dL, Lp(a) was 64.6 nmol/L; in the range of 300–399 mg/dL of TG, Lp(a) decreased to 38. 8 nmol/L, and up to 22.3 nmol/L when TG &gt; 1000 mg/dL.</p></div><div><h3>Conclusions</h3><p>Our results show an inverse Lp(a)–TG relationship in TG concentrations &gt; 300 mg/dL in subjects without diabetes, obesity and without familial hypercholesterolemia. Our results suggest that, in those hypertriglyceridemias due to hepatic overproduction of VLDL, the formation of Lp(a) is reduced, unlike those in which the peripheral catabolism of TG-rich lipoproteins is reduced.</p></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"36 2","pages":"Pages 71-77"},"PeriodicalIF":1.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139075418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Helicobacter pylori a new kid on the block?","authors":"Manuel Vázquez-Carrera","doi":"10.1016/j.arteri.2024.02.002","DOIUrl":"10.1016/j.arteri.2024.02.002","url":null,"abstract":"","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"36 2","pages":"Pages 78-79"},"PeriodicalIF":1.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0214916824000184/pdfft?md5=b84713e5c43be2a88e62f50a1aa2b3e1&pid=1-s2.0-S0214916824000184-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139944537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}